MARKET

PHGE-WS

PHGE-WS

BIOMX
AMEX

Real-time Quotes | Nasdaq Last Sale

0.4530
-0.0024
-0.53%
Opening 15:27 07/28 EDT
OPEN
0.4530
PREV CLOSE
0.4554
HIGH
0.4999
LOW
0.4229
VOLUME
7.16K
TURNOVER
--
52 WEEK HIGH
0.9900
52 WEEK LOW
0.4000
MARKET CAP
--
P/E (TTM)
-0.3243
1D
5D
1M
3M
1Y
5Y
BRIEF-BiomX Inc. Announces $15 Mln Registered Direct Offering
reuters.com · 2d ago
BRIEF-BiomX Presents Preclinical Results With BX005 For Atopic Dermatitis
reuters.com · 06/14 10:49
BRIEF-Biomx To Present Preclinical Results With Bx004 In Cystic Fibrosis At The 44Th European Cystic Fibrosis Conference
reuters.com · 06/09 10:57
BRIEF-Biomx Reports First Quarter 2021 Financial Results And Provides Business Updates
reuters.com · 05/24 10:48
BRIEF-Biomx Reports Phase 2 Study Of Newly Selected Phage Cocktail Candidate Bx005 In Atopic Dermatitis Expected To Initiate In H2 2021
reuters.com · 03/31 10:47
BRIEF-BiomX Announces Dosing Of First Subject In Phase 2 Study Of BX001
reuters.com · 03/02 12:29
From Netflix's 'Queen's Gambit' to HBO's 'Undoing,' here's how the miniseries is leading TVs revolution
Miniseries are back in vogue, and an expert explains why the format -- once left for dead -- is making a comeback.
Yahoo Finance · 02/06 15:38
Super Bowl LV commercials: Cheetos creates buzz, Chipotle drops its first-ever commercial
Cheetos, M&M's, Anheuser-Busch and Chipotle drop primetime ads ahead of Super Bowl Sunday.
Yahoo Finance · 02/06 15:37
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PHGE-WS. Analyze the recent business situations of BIOMX through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
EPS
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.49%
Pharmaceuticals & Medical Research
+1.99%
Key Executives
Chairman/Independent Director
Russell Greig
Chief Executive Officer/Director
Jonathan Solomon
Chief Financial Officer/Vice President - Finance/Vice President - Operations
Marina Wolfson
Other
Merav Bassan
Other
Assaf Oron
Other
Sailaja Puttagunta
Independent Director
Gbola Amusa
Independent Director
Jonas Grossman
Independent Director
Alan Moses
Independent Director
Paul Sekhri
Independent Director
Lynne Sullivan
No Data
About PHGE-WS
BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).

Webull offers kinds of Biomx Inc stock information, including AMEX:PHGE WS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PHGE WS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PHGE-WS stock methods without spending real money on the virtual paper trading platform.